Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 29];9(6):s662. Available from: https://skin.dermsquared.com/skin/article/view/3848